- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BioNexus Gene Lab Corp. Calls for Malaysia-China Biotechnology Cooperation to Move Beyond Trade into Co-Development | 1 | GlobeNewswire (USA) | ||
| 15.05. | BioNexus Gene Lab Corp - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.04. | BioNexus Gene Lab Corp - 10-K, Annual Report | - | SEC Filings | ||
| BIONEXUS GENE LAB Aktie jetzt für 0€ handeln | |||||
| 31.03. | BioNexus Gene Lab Corp - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 17.03. | BioNexus Gene Lab Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 11.03. | BioNexus Gene Lab appoints commercial officer at Fidelion | 2 | Investing.com | ||
| 11.03. | BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard MRD Platform | 813 | GlobeNewswire (Europe) | KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd ("Fidelion") transaction... ► Artikel lesen | |
| 23.02. | BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman | 221 | GlobeNewswire (Europe) | Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp.... ► Artikel lesen | |
| 23.02. | BioNexus Gene Lab Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 03.02. | BioNexus Gene Lab Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 30.12.25 | BioNexus Gene Lab: Aktionäre billigen Vorstand, Eigenkapital-Plan und Wirtschaftsprüfer | 2 | Investing.com Deutsch | ||
| 23.12.25 | BioNexus Gene Lab Corp - 8-K, Current Report | - | SEC Filings | ||
| 02.12.25 | BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization | 194 | GlobeNewswire (Europe) | SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC" or the "Company"), an emerging provider of precision oncology diagnostics with expanding operations across Southeast... ► Artikel lesen | |
| 20.10.25 | BioNexus Gene Lab Corp.: BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. | 466 | GlobeNewswire (Europe) | KUALA LUMPUR, Malaysia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, "BGLC", or the "Company"), today announced that it has entered into a non-binding Strategic Partnership... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DRAEGERWERK | 89,20 | 0,00 % | JEFFERIES stuft Draegerwerk auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Drägerwerk von 73 auf 90 Euro angehoben, aber die Einstufung auf "Hold" belassen. Die Margenentwicklung des Spezialisten... ► Artikel lesen | |
| FRESENIUS | 36,450 | 0,00 % | Während Merck, Amgen, Novo Nordisk und Fresenius Milliarden bewegen, wächst die Fantasie im Zelltherapie-Sektor | ||
| FRESENIUS MEDICAL CARE | 35,690 | 0,00 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung gemäß Artikel 5 Abs. 1 lit. a) der Verordnung (EU) Nr. 596/2014 und Artikel 2 Abs. 1 der Delegierten... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 59,34 | 0,00 % | Morgan Stanley raises BrightSpring Health price target on valuation | ||
| ALIGNMENT HEALTHCARE | 13,640 | 0,00 % | Alignment Healthcare Shows How Earlier, Coordinated Care Leads to Better Health and Fewer Emergencies in 2025 Impact Report | ||
| SIEMENS HEALTHINEERS | 34,040 | 0,00 % | Mentice AB: Mentice and Siemens Healthineers Announce Co-Marketing Partnership to Advance Neurovascular Treatment Planning | Gothenburg, Sweden - June 2026 - Mentice AB, a global leader in simulation and clinical decision support solutions for Image-Guided Therapies, today announced a co-marketing agreement with Siemens Healthineers... ► Artikel lesen | |
| BLUEJAY DIAGNOSTICS | 4,310 | -0,69 % | Morning Market Movers: Bluejay Diagnostics, Decent Holding, Abits Group, Sunshine Biopharma See Big Swings | WASHINGTON (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 26,760 | 0,00 % | Procept Biorobotics wins expanded FDA IDE for Aquablation, completes study enrollment | ||
| PROGYNY | 25,115 | -0,02 % | Progyny, Inc.: New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System | ||
| GENEDX | 53,07 | -0,11 % | Sema4.ai's autonomous agent building platform gets simpler to use, adds deeper business context and more | ||
| BILLIONTOONE | 94,01 | -0,25 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| QTREX QUANTUM | 2,415 | +4,09 % | QTREX Quantum Ltd.: QTREX to Showcase Functional AME-Based Monolithic Connectivity Components for Quantum Computing Systems at Quantum.Tech World 2026 in Boston | ||
| AVEANNA HEALTHCARE | 6,470 | 0,00 % | Aveanna Healthcare Holdings, Inc: Aveanna Healthcare Holdings Completes Acquisition of Family First Homecare and Updates Full Year 2026 Guidance | ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 26,100 | 0,00 % | EQS-DD: Carl Zeiss Meditec AG: Peter Kameritsch, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
28.05.2026 / 14:57... ► Artikel lesen | |
| JIN MEDICAL INTERNATIONAL | 3,220 | -0,92 % | Jin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement | CHANGZHOU, China, April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated... ► Artikel lesen |
Das Unternehmen BIONEXUS GENE LAB CORP kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,61 % bei einem Aktienkurs von 2,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIONEXUS GENE LAB CORP finden Sie auf Wallstreet Online.